Trial Profile
Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerability of ACT-385781A in Japanese children with pulmonary arterial hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2016
Price :
$35
*
At a glance
- Drugs Epoprostenol (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 07 Jun 2016 New trial record